Streptococcus pneumoniae serotype 19A: worldwide epidemiology

References

• Centers for Disease Control and Prevention. Notes from the field: outbreak of severe respiratory illness in an assisted-living facility–Colorado, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:230–231.
   PubMed Web of Science ®Google Scholar
• Simell B, Auranen K, Kayhty H, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11:841–855.
   PubMed Web of Science ®Google Scholar
• Leino T, Auranen K, Jokinen J, et al. Pneumococcal carriage in children during their first two years: important role of family exposure. Pediatr Infect Dis J. 2001;20:1022–1027.
   PubMed Web of Science ®Google Scholar
• Shimada J, Yamanaka N, Hotomi M, et al. Household transmission of Streptococcus pneumoniae among siblings with acute otitis media. J Clin Microbiol. 2002;40:1851–1853.
   PubMed Web of Science ®Google Scholar
• Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25:409–419.
   PubMed Web of Science ®Google Scholar
• Regev-Yochay G, Raz M, Dagan R, et al. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis. 2004;38:632–639.
   PubMed Web of Science ®Google Scholar
• Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144–154.
   PubMed Web of Science ®Google Scholar
• Le Polain de Waroux O, Flasche S, Prieto-Merino D, et al. Age-dependent prevalence of nasopharyngeal carriage of Streptococcus pneumoniae before conjugate vaccine introduction: a prediction model based on a meta-analysis. PLoS One. 2014;9:e86136.
   PubMed Web of Science ®Google Scholar
• Mackenzie GA, Leach AJ, Carapetis JR, et al. Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-sectional surveys in a population with high rates of pneumococcal disease. BMC Infect Dis. 2010;10:304.
   PubMed Web of Science ®Google Scholar
• Mosser JF, Grant LR, Millar EV, et al. Nasopharyngeal carriage and transmission of streptococcus pneumoniae in American Indian households after a decade of pneumococcal conjugate vaccine use. PLoS One. 2014;9:e79578.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Givon-Lavi N, Newman N, et al. Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a means to estimate serotype disease potential. Pediatr Infect Dis J. 2011;30:227–233.
   PubMed Web of Science ®Google Scholar
• Syrjanen RK, Herva EE, Makela PH, et al. The value of nasopharyngeal culture in predicting the etiology of acute otitis media in children less than two years of age. Pediatr Infect Dis J. 2006;25:1032–1036.
   PubMed Web of Science ®Google Scholar
• Petraitiene S, Alasevicius T, Staceviciene I, et al. The influence of Streptococcus pneumoniae nasopharyngeal colonization on the clinical outcome of the respiratory tract infections in preschool children. BMC Infect Dis. 2015;15:403.
   PubMed Web of Science ®Google Scholar
• Gray BM, Converse GM 3rd, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis. 1980;142:923–933.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Trzcinski K, Lu YJ, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009;5:e1000476.
   PubMed Web of Science ®Google Scholar
• Sleeman KL, Griffiths D, Shackley F, et al. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis. 2006;194:682–688.
   PubMed Web of Science ®Google Scholar
• Ampofo K, Pavia AT, Chris S, et al. The changing epidemiology of invasive pneumococcal disease at a tertiary children’s hospital through the 7-valent pneumococcal conjugate vaccine era: a case for continuous surveillance. Pediatr Infect Dis J. 2012;31:228–234.
   PubMed Web of Science ®Google Scholar
• Chiba N, Morozumi M, Shouji M, et al. Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan. Microb Drug Resist. 2013;19:308–315.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur J Pediatr. 2002;161:S135–9.
   PubMed Web of Science ®Google Scholar
• Imohl M, Reinert RR, Ocklenburg C, et al. Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease. J Clin Microbiol. 2010;48:1291–1296.
   PubMed Web of Science ®Google Scholar
• Liesenborghs L, Verhaegen J, Peetermans WE, et al. Trends in serotype prevalence in invasive pneumococcal disease before and after infant pneumococcal vaccination in Belgium, 2002-2010. Vaccine. 2013;31:1529–1534.
   PubMed Web of Science ®Google Scholar
• Olarte L, Ampofo K, Stockmann C, et al. Invasive pneumococcal disease in infants younger than 90 days before and after introduction of PCV7. Pediatrics. 2013;132:e17–24.
   PubMed Web of Science ®Google Scholar
• Saha SK, Hossain B, Islam M, et al. Epidemiology of invasive pneumococcal disease in Bangladeshi children before introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2016;35:655–661.
   PubMed Web of Science ®Google Scholar
• Mehr S, Wood N. Streptococcus pneumoniae–a review of carriage, infection, serotype replacement and vaccination. Paediatr Respir Rev. 2012;13:258–264.
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348. [Epub].
   PubMed Web of Science ®Google Scholar
• PNEUMOVAX® 23 (pneumococcal vaccine polyvalent). Whitehouse Station, NJ 08889, USA: Full Prescribing Information, Merck & Co., Inc.; 2013.
   Google Scholar
• Douglas RM, Paton JC, Duncan SJ, et al. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis. 1983;148:131–137.
   PubMed Web of Science ®Google Scholar
• Prevnar® (pneumococcal. 7-valent conjugate vaccine [diphtheria CRM197 protein]). Philadelphia, PA: Full Prescribing Information, Wyeth Pharmaceuticals, Inc.; 2008.
   Google Scholar
• SYNFLORIX Product Monograph (pneumococcal conjugate vaccine [non-typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates]). Mississauga, ON: Full Prescribing Information, GlaxoSmithKline; 2015.
   Google Scholar
• Prevnar 13® (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]). Collegeville, PA: Full Prescribing Information, Pfizer Inc; 2016.
   Google Scholar
• Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center (IVAC). VIEW-hub Report: Global Vaccine Introduction and Implementation. [ cited 2017 Aug 4]. Available from: http://www.jhsph.edu/research/centers-and-institutes/ivac/view-hub/
   Google Scholar
• Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760–768.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–1973.
   PubMed Web of Science ®Google Scholar
• Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346–1354.
   PubMed Web of Science ®Google Scholar
• Sharma D, Baughman W, Holst A, et al. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J. 2013;32:e45–53.
   PubMed Web of Science ®Google Scholar
• Hanquet G, Kissling E, Fenoll A, et al. Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis. 2010;16:1428–1439.
   PubMed Web of Science ®Google Scholar
• Fenoll A, Aguilar L, Gimenez MJ, et al. Variations in serotypes and susceptibility of adult non-invasive Streptococcus pneumoniae isolates between the periods before (May 2000-May 2001) and 10 years after (May 2010-May 2011) introduction of conjugate vaccines for child immunisation in Spain. Int J Antimicrob Agents. 2012;40:18–23.
   PubMed Web of Science ®Google Scholar
• Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:e197–209.
   PubMed Web of Science ®Google Scholar
• Cho EY, Kang HM, Lee J, et al. Changes in serotype distribution and antibiotic resistance of nasopharyngeal isolates of Streptococcus pneumoniae from children in Korea, after optional use of the 7-valent conjugate vaccine. J Korean Med Sci. 2012;27:716–722.
   PubMed Web of Science ®Google Scholar
• Thoon KC, Chong CY, Tee NW. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010. Int J Infect Dis. 2012;16:e209–15.
   PubMed Web of Science ®Google Scholar
• Lehmann D, Willis J, Moore HC, et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis. 2010;50:1477–1486.
   PubMed Web of Science ®Google Scholar
• Choi EH, Kim SH, Eun BW, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis. 2008;14:275–281.
   PubMed Web of Science ®Google Scholar
• Jefferies JM, Smith AJ, Edwards GF, et al. Temporal analysis of invasive pneumococcal clones from Scotland illustrates fluctuations in diversity of serotype and genotype in the absence of pneumococcal conjugate vaccine. J Clin Microbiol. 2010;48:87–96.
   PubMed Web of Science ®Google Scholar
• Ruckinger S, Von Kries R, Reinert RR, et al. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination. Vaccine. 2008;26:3984–3986.
   PubMed Web of Science ®Google Scholar
• Flamaing J, Verhaegen J, Vandeven J, et al. Pneumococcal bacteraemia in Belgium (1994 2004): the pre-conjugate vaccine era. J Antimicrob Chemother. 2008;61:143–149.
   PubMed Web of Science ®Google Scholar
• Henriques-Normark B, Blomberg C, Dagerhamn J, et al. The rise and fall of bacterial clones: streptococcus pneumoniae. Nat Rev Microbiol. 2008;6:827–837.
   PubMed Web of Science ®Google Scholar
• Varon E, Cohen R, Bechet S, et al. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. Vaccine. 2015;33:6178–6185.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis. 2010;51:692–699.
   PubMed Web of Science ®Google Scholar
• Moore MR, Gertz RE Jr., Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197:1016–1027.
   PubMed Web of Science ®Google Scholar
• Brueggemann AB, Pai R, Crook DW, et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. 2007;3:e168.
   PubMed Web of Science ®Google Scholar
• Olarte L, Hulten KG, Lamberth L, et al. Impact of the 13-valent pneumococcal conjugate vaccine on chronic sinusitis associated with Streptococcus pneumoniae in children. Pediatr Infect Dis J 2014;33:1033–1036.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010;125:429–436.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Center KJ, Barson WJ, et al. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era. Clin Infect Dis 2015;60:1339–1345.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Mason EO, Jr., Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004;113:443–449.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Synflorix. Pneumococcal polysaccharide conjugate vaccine (adsorbed). EPAR summary for the public. [cited 2017 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/1050human/000973/WC500054347.pdf.
   Google Scholar
• Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®]. Drugs. 2010;70:1973–1986.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for Prevenar 13. [ cited 2017 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001104/WC500057250.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59:258–261.
   PubMedGoogle Scholar
• Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr. 2010;10:4.
   PubMed Web of Science ®Google Scholar
• Expert WHO Committee on Biological Standarization. WHO TechnicalReport Series 927. [cited 2017 Aug 4]. Available from: http://www.who.int/biologicals/WHO_TRS_%20927%20full%20tex.pdf
   Google Scholar
• Jodar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003;21:3265–3272.
   PubMed Web of Science ®Google Scholar
• Poolman JT, Frasch CE, Kayhty H, et al. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol. 2010;17:134–142.
   PubMed Web of Science ®Google Scholar
• Johnson SE, Rubin LRomero-Steiner S, et al. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for streptococcus pneumoniae. J Infect Dis 1999;180:133–140.
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997;4:415–422.
   PubMedGoogle Scholar
• Romero-Steiner S, Frasch CE, Carlone G, et al. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006;13:165–169.
   PubMed Web of Science ®Google Scholar
• Gruber WC, Scott DA, Emini EA. Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine. Ann N Y Acad Sci 2012;1263:15–26.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28:S66–76.
   PubMed Web of Science ®Google Scholar
• Kim CH, Kim JS, Cha SH, et al. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants. Pediatr Infect Dis J. 2011;30:e235–43.
   PubMed Web of Science ®Google Scholar
• Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J. 2009;28:S89–96.
   PubMed Web of Science ®Google Scholar
• Bermal N, Szenborn L, Edison A, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines. Pediatr Infect Dis J. 2011;30:69–72.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Clinical Study Report for Study 105539. [ cited 2017 Aug 4]. Available from: http://www.gsk-clinicalstudyregister.com/study/105539#csr
   Google Scholar
• Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009;28:S77–88.
   PubMed Web of Science ®Google Scholar
• van den Bergh MR, Spijkerman J, Francois N, et al. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J. 2011;30:e170–8.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease. Expert Rev Vaccines. 2015;14:1359–1366.
   PubMed Web of Science ®Google Scholar
• Yu X, Gray B, Chang S, et al. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis. 1999;180:1569–1576.
   PubMed Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192–4203.
   PubMed Web of Science ®Google Scholar
• Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493–505.
   PubMed Web of Science ®Google Scholar
• Henckaerts I, Goldblatt D, Ashton L, et al. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13:356–360.
   Google Scholar
• Frenck RW Jr., Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19:1296–1303.
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–18.
   PubMedGoogle Scholar
• Schwarz TF, Schmoele-Thoma B. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years. Vaccine. 2013;31:291–294.
   PubMed Web of Science ®Google Scholar
• Juergens C, Patterson S, Trammel J, et al. Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization. Clin Vaccine Immunol. 2014;21:1277–1281.
   PubMed Web of Science ®Google Scholar
• Avila-Aguero ML, Ulloa-Gutierrez R, Falleiros-Arlant LH, et al. Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?. Expert Rev Vaccines. 2017;16:1–4.
   Web of Science ®Google Scholar
• Van Westen E, Wijmenga-Monsuur AJ, Van Dijken HH, et al. Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2015;61:342–349.
   PubMed Web of Science ®Google Scholar
• Wijmenga-Monsuur AJ, van Westen E, Knol MJ, et al. Direct comparison of immunogenicity induced by 10- or 13-valent pneumococcal conjugate vaccine around the 11-month booster in Dutch infants. PLoS One. 2015;10:e0144739.
   Google Scholar
• GlaxoSmithKline. Clinical Study Report for study 116485. [ cited 2017 Aug 4]. Available from: http://www.gsk-clinicalstudyregister.com/study/116485?study_ids=116485#rs
   Google Scholar
• Truck J, Jawad S, Goldblatt D, et al. The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy. Pediatr Infect Dis J. 2016;35:787–793.
   PubMed Web of Science ®Google Scholar
• Prymula R, Urbancikova I, Goldblatt D, et al. A booster dose of PCV13 In children primed with 2 or 3-doses of PHiD-CV – possible alternative immunization strategy? Presented at: 10th International Symposium of Pneumococci and Pneumococcal Diseases (ISPPD-10); 2016; Glasgow, Scotland, UK
   Google Scholar
• Moore MR, Hyde TB, Hennessy TW, et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis. 2004;190:2031–2038.
   PubMed Web of Science ®Google Scholar
• Roca A, Bojang A, Bottomley C, et al. Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia. Vaccine. 2015;33:7144–7151.
   PubMed Web of Science ®Google Scholar
• Brandileone MC, Zanella RC, Almeida SC, et al. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and haemophilus influenzae among children in Sao Paulo, Brazil. Vaccine. 2016;34:5604–5611.
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Sheppard CL, Andrews NJ, et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014;32:4349–4355.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Givon-Lavi N, Greenberg D, et al. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel. Hum Vaccin Immunother. 2016;12:268–276.
   PubMed Web of Science ®Google Scholar
• Desai AP, Sharma D, Crispell EK, et al. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J. 2015;34:1168–1174.
   PubMed Web of Science ®Google Scholar
• Lee GM, Kleinman K, Pelton SI, et al. Impact of 13-valent pneumococcal conjugate vaccination on carriage in young children in Massachusetts. J Pediatric Infect Dis Soc. 2014;3:23–32.
   PubMedGoogle Scholar
• Dunais B, Bruno P, Touboul P, et al. Impact of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae among children attending group daycare in southeastern France. Pediatr Infect Dis J. 2015;34:286–288.
   PubMed Web of Science ®Google Scholar
• Best EJ, Walls T, Souter M, et al. Pneumococcal vaccine impact on otitis media microbiology: a New Zealand cohort study before and after the introduction of PHiD-CV10 vaccine. Vaccine. 2016. DOI:10.1016/j.vaccine.2016.05.041
   PubMed Web of Science ®Google Scholar
• Loughlin AM, Hsu K, Silverio AL, et al. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J. 2014;33:504–510.
   PubMed Web of Science ®Google Scholar
• Bosch AA, van Houten MA, Bruin JP, et al. Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands. Vaccine. 2016;34:531–539.
   PubMed Web of Science ®Google Scholar
• Mameli C, Fabiano V, Daprai L, et al. A longitudinal study of Streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine era. Hum Vaccin Immunother. 2015;11:811–817.
   PubMed Web of Science ®Google Scholar
• Spijkerman J, Prevaes SM, van Gils EJ, et al. Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PLoS One. 2012;7:e39730.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health. 2014;2:e397–405.
   PubMed Web of Science ®Google Scholar
• Cohen R, Varon E, Doit C, et al. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine. 2015;33:5118–5126.
   PubMed Web of Science ®Google Scholar
• Zuccotti G, Mameli C, Daprai L, et al. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine. 2014;32:527–534.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Seppa I, et al. Effectiveness of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugated vaccine (PHiD-CV) against carriage and acute otitis media-a double-blind randomized clinical trial in Finland. J Pediatric Infect Dis Soc. 2016;5:237–248. DOI: 10.1093/jpids/piw010
   PubMed Web of Science ®Google Scholar
• Kellner JD, Scheifele D, Vanderkooi OG, et al. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J. 2008;27:526–532.
   PubMed Web of Science ®Google Scholar
• Kuo CY, Hwang KP, Hsieh YC, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Taiwan before and after the introduction of a conjugate vaccine. Vaccine. 2011;29:5171–5177.
   PubMed Web of Science ®Google Scholar
• Chan KC, Subramanian R, Chong P, et al. Pneumococcal carriage in young children after introduction of PCV13 in Hong Kong. Vaccine. 2016;34:3867–3874.
   PubMed Web of Science ®Google Scholar
• Soysal A, Karabag-Yilmaz E, Kepenekli E, et al. The impact of a pneumococcal conjugate vaccination program on the nasopharyngeal carriage, serotype distribution and antimicrobial resistance of Streptococcus pneumoniae among healthy children in Turkey. Vaccine. 2016;34:3894–3900.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10:e1001517.
   PubMed Web of Science ®Google Scholar
• Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369:155–163.
   PubMed Web of Science ®Google Scholar
• Demczuk WH, Martin I, Griffith A, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol. 2013;59:778–788.
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Fraser D, et al. Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005;192:367–376.
   PubMed Web of Science ®Google Scholar
• Jokinen JT, Ahman H, Kilpi TM, et al. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis. 2004;190:545–550.
   PubMed Web of Science ®Google Scholar
• Millar EV, O’Brien KL, Bronsdon MA, et al. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1173–1179.
   PubMed Web of Science ®Google Scholar
• Simell B, Nurkka A, Lahdenkari M, et al. Association of serotype-specific antibody concentrations and functional antibody titers with subsequent pneumococcal carriage in toddlers immunized with a 9-valent pneumococcal conjugate vaccine. Clin Vaccine Immunol. 2012;19:96–99.
   PubMed Web of Science ®Google Scholar
• Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57:952–962.
   PubMed Web of Science ®Google Scholar
• van den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013;56:e30–9.
   PubMed Web of Science ®Google Scholar
• Wyllie AL, Wijmenga-Monsuur AJ, van Houten MA, et al. Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in children vaccinated with conjugated polysaccharide pneumococcal vaccines. Sci Rep. 2016;6:23809.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. COMPAS: a phase III study to demonstrate efficacy of GSK Biologicals’ 10-valent pneumococcal vaccine (GSK1024850A) against community acquired pneumonia and acute otitis media. [ cited 2017 Aug 4]. Available from: http://www.gsk-clinicalstudyregister.com/study/109563#rs
   Google Scholar
• GlaxoSmithKline. Clinical study report for study 112595. Impact on nasopharyngeal carriage, acute otitis media, immunogenicity and safety of GSK Biologicals pneumococcal vaccine 1024850A. [ cited 2017 Aug 4]. Available from: https://www.gsk-clinicalstudyregister.com/study/112595?study_ids=112595#csr
   Google Scholar
• Prymula R, Habib A, Francois N, et al. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. Vaccine. 2013;31:2080–2088.
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012;31:297–301.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Givon-Lavi N, Leibovitz E, et al. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis. 2014;59:1724–1732.
   PubMed Web of Science ®Google Scholar
• Olarte L, Barson WJ, Barson RM, et al. Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children. Clin Infect Dis. 2015;61:767–775.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32:203–207.
   PubMed Web of Science ®Google Scholar
• Iroh Tam PY, Madoff LC, Coombes B, et al. Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics. 2014;134:210–217.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–309.
   PubMed Web of Science ®Google Scholar
• Farnham AC, Zimmerman CM, Papadouka V, et al. Invasive pneumococcal disease following the introduction of 13-valent conjugate vaccine in children in New York City from 2007 to 2012. JAMA Pediatr. 2015;169:646–652.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4:399–406.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14:839–846.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15:535–543.
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59:1066–1073.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32:3452–3459.
   PubMed Web of Science ®Google Scholar
• Wei SH, Chiang CS, Chiu CH, et al. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34:e71–7.
   PubMed Web of Science ®Google Scholar
• von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014;371:1889–1899.
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varon E, Georges S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015;33:359–366.
   PubMed Web of Science ®Google Scholar
• Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain. Clin Vaccine Immunol. 2013;20:1524–1530.
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Serres G, Boulianne N, et al. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33:2684–2689.
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2:464–471.
   PubMed Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. PLoS One. 2015;10:e0120290.
   PubMed Web of Science ®Google Scholar
• Lefebvre B. Programme de surveillance du pneumocoque: rapport 2013. [ cited 2017 Aug 4]. Available from: https://www.inspq.qc.ca/pdf/publications/1946_Programme_Surveillance_Pneumocoque.pdf
   Google Scholar
• Pan American Health Organization. SIREVA II (Sistema de Redes de Vigilancia de los Agentes Responsables do Neumonias y Meningitis Bacterianas). [ cited 2017 Aug 4]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=3609&Itemid=3953
   Google Scholar
• Instituto de Salud Publica de Chile. Boletin Instituto de Salud Publica de Chile. Julio 2015. Vigilancia de laboratorio de Streptococcus pneumoniae procedente de enfermedad invasora. Chile, 2007-2015. [cited 2017 Aug 4]. Available from: http://www.ispch.cl/sites/default/files/Boletín%20de%20Vigilancia%20de%20Laboratorio%20de%20Streptococcus%20pneumoniae.pdf
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance atlas of infectious diseases - invasive pneumococcal disease. [ cited 2017 Aug 7]. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Surveillance%20of%20IBD%20in%20Europe%202012.pdf
   Google Scholar
• National Institute for Health and Welfare. Incidence of invasive pneumococcal disease in Finland. [ cited 2017 Aug 4]. Available from: https://www.thl.fi/en/web/thlfi-en/topics/information-packages/incidence-of-invasive-pneumococcal-disease-in-finland
   Google Scholar
• Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31:6232–6238.
   PubMed Web of Science ®Google Scholar
• Public Health Surveillance. Information for New Zealand public health action. Invasive Pneumococcal Disease Reports. [ cited 2017 Aug 4]. Available from: https://surv.esr.cri.nz/surveillance/IPD.php
   Google Scholar
• Sings HL. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine. 2017. [Epub ahead of print].
   PubMedGoogle Scholar
• Centers for Disease Control. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep. 2010;59:253–257.
   PubMedGoogle Scholar
• Ladhani SN, Andrews NJ, Waight P, et al. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and Wales. Clin Infect Dis. 2013;56:633–640.
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varon E, Georges S, et al. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill. 2008;13(35):1–6.
   Google Scholar
• Ozawa D, Yano H, Endo S, et al. Impact of the seven-valent pneumococcal conjugate vaccine on acute otitis media in japanese children: emergence of serotype 15A multidrug-resistant Streptococcus pneumoniae in middle ear fluid isolates. Pediatr Infect Dis J. 2015;34:e217–21.
   PubMed Web of Science ®Google Scholar
• Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28:4249–4259.
   PubMed Web of Science ®Google Scholar
• Langley G, Schaffner W, Farley MM, et al. Twenty years of active bacterial core surveillance. Emerg Infect Dis. 2015;21:1520–1528.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495–1502.
   PubMed Web of Science ®Google Scholar
• Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988–1995.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41.
   PubMed Web of Science ®Google Scholar
• Richter SS, Heilmann KP, Dohrn CL, et al. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis. 2013;19:1074–1083.
   PubMed Web of Science ®Google Scholar
• Public Health England. Health protection report. Quarterly vaccination coverage statistics for children aged up to five years in the UK (COVER programme): April to June 2011. [ cited 2017 Aug 4]. Available from: http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/hpr/archives/2011/hpr3811.pdf
   Google Scholar
• Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381:214–222.
   PubMed Web of Science ®Google Scholar
• Finnish National Institute for Health and Welfare. Incidence of invasive pneumococcal disease in Finland. [ cited 2017 Aug 4]. Available from: https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/projects-and-programmes/monitoring-the-population-effectiveness-of-pneumococcal-conjugate-vaccination-in-the-finnish-national-vaccination-programme/incidence-of-invasive-pneumococcal-disease-in-finland
   Google Scholar
• Cassiolato A, Almeida S, Guerra M, et al. Changes in invasive Streptococcus pneumoniae serotype (Spn) 19A after introduction of 10-valent pneumococcal conjugate vaccine (PCV10) in Brazil. Presented at: 9th Wold Congress of the World Society for Pediatric Infectious Diseases (WSPID); 2015; Rio de Janiero, Brazil
   Google Scholar
• Andrade AL, Minamisava R, Policena G, et al. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: a time-series analysis. Hum Vaccin Immunother. 2016;12:285–292.
   PubMed Web of Science ®Google Scholar
• Verani JR, Domingues CM, Moraes JC, et al. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease. Vaccine. 2015;33:6145–6148.
   PubMed Web of Science ®Google Scholar
• Diaz J, Terrazas S, Bierrenbach AL, et al. Effectiveness of the 10-valent pneumococcal conjugate vaccine (PCV-10) in children in Chile: a nested case-control study using nationwide pneumonia morbidity and mortality surveillance data. PLoS One. 2016;11:e0153141.
   PubMed Web of Science ®Google Scholar
• Potin M, Fica A, Wilhem J, et al. Statement of the Advisory Immunization Committee of the Chilean Society of Infectious Diseases on the emergence of serotype 19A pneumococcal infection and the use of pneumococcal conjugated vaccine in Chilean children. Rev Chilena Infectol. 2016;33:304–306.
   PubMed Web of Science ®Google Scholar
• Lim E, Heffernan H. Invasive pneumococcal disease quarterly report. 2013 January-March. [ cited 2017 Aug 4]. Available from: https://surv.esr.cri.nz/PDF_surveillance/IPD/2014/2014Q1_IPDReport.pdf
   Google Scholar
• New Zealand Ministry of Health. National immunisation coverage data tables. [ cited 2017 Aug 4]. Available from: http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/immunisation-coverage/national-and-dhb-immunisation-data
   Google Scholar
• Institute of Environmental Science and Research Limited. Public health surveillance. Information for New Zealand public health action. [ cited 2017 Aug 4]. Available from: https://surv.esr.cri.nz/index.php
   Google Scholar
• Institute of Environmental Science and Research Ltd (ESR). Invasive pneumococcal disease in New Zealand. Wellington (NZ): Ministry of Health; 2014. [ cited 2017 Aug 4]. Available from https://surv.esr.cri.nz/PDF_surveillance/IPD/2014/2014IPDAnnualReport.pdf.
   Google Scholar
• Institute of Environmental Science and Research Ltd (ESR). Invasive pneumococcal disease in New Zealand. Wellington (NZ): Ministry of Health; 2013 [ cited 2017 Aug 4]. Available at https://surv.esr.cri.nz/PDF_surveillance/IPD/2013/2013AnnualIPDRpt.pdf.
   Google Scholar
• Roos R, Heffernan H. Invasive pneumococcal disease quarterly report. 2014 October-December. [cited 2017 Aug 7]. Available from: https://surv.esr.cri.nz/PDF_surveillance/IPD/2014/2014Q1_IPDReport.pdf
   Google Scholar
• Borman A, Heffernan H. Invasive pneumococcal disease quarterly report. October-December 2015. [ cited 2017 Aug 4]. Available from: https://surv.esr.cri.nz/surveillance/IPD.php
   Google Scholar
• Knol MJ, Wagenvoort GH, Sanders EA, et al. Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis. 2015;21:2040–2044.
   PubMed Web of Science ®Google Scholar
• Alberts N, Barug D, Benschop K, et al. The national immunisation programme in the Netherlands, surveillance and developments in 2015-2016. National Institute for Public Health and the Environment, Ministry of Health, Welfare and Sport, the Hague, Netherlands. [cited 2017 Aug 4]. Available from: http://www.rivm.nl/bibliotheek/rapporten/2016-0141.pdf
   Google Scholar
• Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis. 2008;8:785–795.
   PubMed Web of Science ®Google Scholar
• Wei SH, Chiang CS, Chen CL, et al. Pneumococcal disease and use of pneumococcal vaccines in Taiwan. Clin Exp Vaccine Res. 2015;4:121–129.
   PubMed Web of Science ®Google Scholar
• Calatayud L, Ardanuy C, Tubau F, et al. Serotype and genotype replacement among macrolide-resistant invasive Pneumococci in adults: mechanisms of resistance and association with different transposons. J Clin Microbiol. 2010;48:1310–1316.
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455–1463.
   PubMed Web of Science ®Google Scholar
• Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012;56:1418–1426.
   PubMed Web of Science ®Google Scholar
• Caierao J, Hawkins P, Sant’anna FH, et al. Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern Brazil. PLoS One. 2014;9:e111129.
   PubMed Web of Science ®Google Scholar
• Dagan R, Juergens C, Trammel J, et al. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae. J Infect Dis. 2015;211:1144–1153.
   PubMed Web of Science ®Google Scholar
• Angoulvant F, Cohen R, Doit C, et al. Trends in antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from nasopharyngeal flora in children with acute otitis media in France before and after 13-valent pneumococcal conjugate vaccine introduction. BMC Infect Dis. 2015;15:236.
   PubMed Web of Science ®Google Scholar
• Kempf M, Varon E, Lepoutre A, et al. Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001-2011 survey by the French Pneumococcal Network. Clin Microbiol Infect. 2015;21:35–42.
   PubMed Web of Science ®Google Scholar
• Janoir C, Lepoutre A, Gutmann L, et al. Insight into resistance phenotypes of emergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolated from invasive disease after 13-valent pneumococcal conjugate vaccine implementation in France. Open Forum Infect Dis. 2016;3:ofw020.
   PubMed Web of Science ®Google Scholar
• Metcalf BJ, Gertz RE Jr., Gladstone RA, et al. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect. 2016;22:60.e9-60.e29.
   Web of Science ®Google Scholar
• Tomczyk S, Lynfield R, Schaffner W, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016;62:1119–1125.
   PubMed Web of Science ®Google Scholar
• Rudolph K, Bruce M, Bulkow L, et al. Clonal diversity of penicillin-nonsusceptible invasive pneumococal isolates in Alaska, 2001-2014. Presented at: 10th International Symposium on Pneumococci and Pneumococcal Disease (ISPPD); 2016; Glasgow, Scotland, UK
   Google Scholar
• Moreira M, Cintra O, Harriague J, et al. Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program. Vaccine. 2016;34:2766–2778.
   PubMed Web of Science ®Google Scholar
• Beall BW, Gertz RE, Hulkower RL, et al. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis. 2011;203:1360–1368.
   PubMed Web of Science ®Google Scholar
• Afonso ET, Minamisava R, Bierrenbach AL, et al. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis. 2013;19:589–597.
   PubMed Web of Science ®Google Scholar
• O’Halloran AC, Lu PJ, Pilishvili T. Pneumococcal vaccination coverage among persons >/=65 years–United States, 2013. Vaccine. 2015;33:5503–5506.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30:6802–6808.
   PubMed Web of Science ®Google Scholar
• Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther. 2014;31:1011–1044.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for prevenar 13. [ cited 2017 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001104/WC500119784.pdf
   Google Scholar
• Suzuki M, Dhoubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17:313–321.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Clinical study report for study 116485. Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants. [ cited 2017 Aug 4]. Available from: http://www.gsk-clinicalstudyregister.com/study/116485#rs
   Google Scholar
• De Oliveira LH, Camacho LA, Coutinho ES, et al. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016;11:e0166736.
   PubMed Web of Science ®Google Scholar
• Hanquet G, Savulescu C. Indirect effect of infant PCV10/13 vaccination on IPD in the elderly: pooled analysis from 13 EU sites. [ cited 2017 Aug 4]. Available from: https://www.slideshare.net/ECDC_EU/germaine-hanquet-indirect-effect-of-infant-pcv1013-vaccination-on-ipd-in-the-elderly-pooled-analysis-from-13-eu-sites
   Google Scholar
• Hanquet G, Celentano LP, Savulescu C, et al. Invasive H influenzae Disease ECDC Country Experts, Celentano LP, et al. Which pneumococcal vaccine for the elderly? Indirect effect of childhood PCV10/13 vaccination on invasive pneumococcal disease in the elderly of 10 European countries. Presented at: 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2017; Vienna, Austria
   Google Scholar
• Castaneda-Orjuela C, Alvis-Guzman N, Velandia-Gonzalez M, et al. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Vaccine. 2012;30:1936–1943.
   PubMed Web of Science ®Google Scholar
• de Oliveira LH, Trumbo SP, Ruiz Matus C, et al. Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned. Expert Rev Vaccines. 2016;15:1295–1304.
   PubMed Web of Science ®Google Scholar
• Ordonez JE, Orozco JJ. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia. Cost Eff Resour Alloc. 2015;13:6.
   PubMed Web of Science ®Google Scholar
• Strutton DR, Farkouh RA, Earnshaw SR, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect. 2012;64:54–67.
   PubMed Web of Science ®Google Scholar
• Newall AT, Creighton P, Philp DJ, et al. The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine. 2011;29:8077–8085.
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, McDade CL, Zanotti G, et al. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis. 2012;12:101.
   PubMed Web of Science ®Google Scholar
• Mucino-Ortega E, Mould-Quevedo JF, Farkouh R, et al. Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines. Value Health. 2011;14:S65–70.
   PubMed Web of Science ®Google Scholar
• Wasserman M, Wilson M, Breton MC, et al. Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to a lower-valent (PCV10) vaccine in Canada. Presented at: 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2017 May 23-27; Madrid
   Google Scholar
• Wasserman M, Rejas J, Mendez C, et al. Estimating clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Spain. Presented at: 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 23-27, 2017; Madrid
   Google Scholar